Danny Kharazmi


Admitted to the Ontario Bar: 2014

Danny thrives on finding effective and creative solutions to help clients navigate through highly-regulated industries. By carefully considering the needs and goals of his clients, he provides an array of value-added solutions in relation to securities and corporate law matters.

Danny is a member of the firm’s Capital Markets Group. His practice focuses on debt and equity financings, going public transactions, mergers and acquisitions and regulatory compliance. He also advises on continuous disclosure obligations and corporate governance matters. Danny represents issuers and investment dealers in a broad range of industries, including cannabis, biotech, E-sports, mining, energy, entertainment and Fintech.

Danny is also an adjunct professor at Osgoode Hall Law School. 

Danny holds a JD/MBA from the University of Ottawa as well as a BA from the University of Toronto and a Master’s of Public Administration from Queen’s University. While a law student, Danny was selected as a Dean’s fellow and worked as a teaching assistant for the Dean’s Legal Research and Writing courses. Danny was also active in his law school's moot court program. His team placed second in the World Trade Organization Moot Competition in 2012.

Professional Involvement


Law Society of Ontario

Representative Matters

Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of an overnight marketed offering pursuant to a prospectus supplement to Cybin's short form base shelf prospectus, with aggregate gross proceeds of approximately $34 million.

Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.

Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of a bought deal short form prospectus offering of units for aggregate gross proceeds of approximately $34 million.

Represented Cybin Inc. (the “Company”) (NEO: CYBN) in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.

Selected Publications

"Legal and Regulatory Landscape for Psychedelics Companies Considering Going Public in Canada," Aird & Berlis LLP's Capital Markets Newsletter, July 8, 2020. 


  • JD, University of Ottawa, 2013
  • MBA, University of Ottawa, 2013
  • MPA, Queen's University, 2006
  • BA (Honours), University of Toronto, 2005